Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb , Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-explorating Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).

Next Previous
X
Search
Trial Profile

A Phase IIb , Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-explorating Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telitacicept (Primary) ; Azathioprine; Ciclosporin; Cyclophosphamide; Leflunomide; Methotrexate; Mycophenolate; Tacrolimus
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors RemeGen

    • Most Recent Events

    • 12 Dec 2023 Results assessing efficacy and safety of telitacicept in active systemic lupus erythematosus, published in the Annals of the Rheumatic Diseases.
    • 02 Mar 2020 Status changed from active, no longer recruiting to completed.
    • 15 Nov 2019 According to an RemeGen media release, Dr. Wu is the lead investigator of the trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top